# ZEPBOUND

NDC: 0002-2457
Generic name: tirzepatide
Labeler / Manufacturer: Eli Lilly and Company
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: New Drug Application (innovator)
Dosage form: INJECTION, SOLUTION
Routes: SUBCUTANEOUS
Marketing started: 20231108

FDA application: NDA217806

## Active ingredients

- TIRZEPATIDE: 15 mg/.5mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"0002-2457"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=0002-2457
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b